Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 10/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302008 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL13621266 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL12029778 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL10041945 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL15119375 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL331945 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL2467656 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL19657131 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL10013535 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL13126803 | 1.00 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017931-A1 | METHODS OF PERSONALIZING CANCER TREATMENT | PROCESSA PHARMACEUTICALS, INC., (US) | 2025-01-16 | — | — | US | claimed |
| US-20240299554-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | PHARMACYTICS B.V. (NL) | 2024-09-12 | — | — | US | claimed |
| EP-4359419-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | Pharmacytics B.V. (NL) | 2024-05-01 | — | — | EP | claimed |
| CN-117858882-A | Prodrugs having 1- (disulfanyl) alkoxy-carbonyl units | 药物有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117603286-A | Preparation and application of lysosome-targeted aging cell removal prodrug | 江南大学 | 2024-02-27 | — | — | CN | claimed |
| EP-4260874-A1 | CLEAVABLE POLYMER DRUG CONJUGATES | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Anonim Sirketi (TR) | 2023-10-18 | — | — | EP | claimed |
| EP-3478323-B1 | CLEAVABLE POLYMER DRUG CONJUGATES | RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI (TR) | 2023-09-27 | — | — | EP | claimed |
| US-20230172960-A1 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-06-08 | — | — | US | claimed |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | claimed |
| US-11559541-B2 | Topical capecitabine for the treatment of hyperproliferative skin conditions | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-01-24 | — | — | US | claimed |
| EP-1461122-A2 | TREATMENT OF GENITOURINARY TRACT DISORDERS | Control Delivery Systems, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1448231-A1 | TOPICAL DELIVERY OF CODRUGS | Control Delivery Systems, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030203030-A1 | Polymeric gel delivery system for pharmaceuticals | CONTROL DELIVERY SYSTEMS, INC. | 2003-10-30 | — | — | US | claimed |
| US-20030170286-A1 | Treatment of genitourinary tract disorders | CONTROL DELIVERY SYSTEMS, INC. | 2003-09-11 | — | — | US | claimed |
| WO-2003061626-A1 | POLYMERIC GEL SYSTEM FOR THE CONTROLLED DELIVERY OF CODRUGS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030118528-A1 | Topical delivery of codrugs | CONTROL DELIVERY SYSTEMS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003049804-A2 | TREATMENT OF GENITOURINARY TRACT DISORDERS | CONTROL DELIVERY SYSTEMS INC. (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2003043657-A1 | TOPICAL DELIVERY OF CODRUGS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-0316704-B1 | Fluorocytidine derivatives, their preparation and medical preparations containing them | HOFFMANN LA ROCHE (CH) | 1995-07-12 | — | — | EP | claimed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118528-A1 | Topical delivery of codrugs | DSG1, CCR7, CUTA | LMNA 1847/4885TSHR 4725/4885MAPT 832/4885 |
| US-20240299554-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | SI, SULT1E1, SULT1A1 | LMNA 3632/4885TSHR 3169/4885MAPT 3457/4885 |
| US-20030170286-A1 | Treatment of genitourinary tract disorders | GLS, FOLH1, KLK3 | LMNA 3621/4885TSHR 2871/4885MAPT 2064/4885 |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | LMNA 3041/4885TSHR 1801/4885MAPT 565/4885 |
| US-20030203030-A1 | Polymeric gel delivery system for pharmaceuticals | MMP1, IL6, CD44 | LMNA 3997/4885TSHR 4559/4885MAPT 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.